Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 4
2001 4
2002 3
2003 3
2004 8
2005 3
2006 9
2007 4
2008 9
2009 7
2010 16
2011 12
2012 12
2013 12
2014 6
2015 6
2016 4
2017 8
2018 5
2019 5
2020 3
2021 6
2022 7
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Maurer MJ, et al. Among authors: micallef in. J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18. J Clin Oncol. 2014. PMID: 24550425 Free PMC article. Clinical Trial.
Long-term outcome of immunologic autograft engineering.
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Paludo J, Markovic SN. Porrata LF, et al. Among authors: micallef in. EJHaem. 2022 Feb 24;3(2):488-491. doi: 10.1002/jha2.404. eCollection 2022 May. EJHaem. 2022. PMID: 35846064 Free PMC article.
Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB, Bondly C, Micallef IN. Johnston PB, et al. Among authors: micallef in. Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9. doi: 10.1586/14737140.6.6.861. Expert Rev Anticancer Ther. 2006. PMID: 16761929 Review.
History of autoimmune conditions and lymphoma prognosis.
Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR. Kleinstern G, et al. Among authors: micallef in. Blood Cancer J. 2018 Aug 1;8(8):73. doi: 10.1038/s41408-018-0105-4. Blood Cancer J. 2018. PMID: 30069001 Free PMC article.
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Kapoor P, et al. Among authors: micallef in. JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. JAMA Oncol. 2017. PMID: 28056114 Free PMC article. Review.
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J. Kraft RM, et al. Among authors: micallef in. Hematol Oncol. 2021 Dec;39(5):658-663. doi: 10.1002/hon.2919. Epub 2021 Aug 28. Hematol Oncol. 2021. PMID: 34453851
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.
Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. Wagner CB, et al. Among authors: micallef in. Haematologica. 2023 Nov 1;108(11):3025-3032. doi: 10.3324/haematol.2023.282780. Haematologica. 2023. PMID: 37102592 Free PMC article.
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
Chohan KL, Young JR, Lester S, Moustafa MA, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM. Chohan KL, et al. Among authors: micallef in. Haematologica. 2023 Jun 1;108(6):1697-1701. doi: 10.3324/haematol.2022.282115. Haematologica. 2023. PMID: 36546451 Free PMC article. No abstract available.
148 results